Piermont Capital Management’s ResMed RMD Stock Holding History

Piermont Capital Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-10,940	Closed	-$692K	–	275
2016 Q2	$692K	Buy	10,940 +6,350	+138%	+$374K	0.18%	200
2016 Q1	$265K	Hold	4,590	–	–	0.08%	211
2015 Q4	$246K	Hold	4,590	–	–	0.08%	216
2015 Q3	$234K	Hold	4,590	–	–	0.08%	212
2015 Q2	$259K	Hold	4,590	–	–	0.08%	210
2015 Q1	$329K	Buy	+4,590	New	+$298K	0.1%	201

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Piermont Capital Management's RMD Position: Q3 2016 in Review

Piermont Capital Management sold out of ResMed (RMD) in Q3 2016, closing a stake of 10,940 shares — an estimated $692K sold.

Piermont Capital Management first reported a position in RMD in Q1 2015 and held it in 6 quarters. The position peaked at $692K in Q2 2016. 373 funds tracked by Wall St. Rank hold RMD as of Q3 2016.

Piermont Capital Management reported no remaining ResMed position as of Q3 2016 after selling out during the quarter.
Piermont Capital Management sold 10,940 ResMed shares in Q3 2016, an estimated $692K.
Piermont Capital Management first reported a position in ResMed in Q1 2015 and held it in 6 quarters.
Piermont Capital Management's ResMed position peaked at $692K in Q2 2016.
373 funds tracked by Wall St. Rank held ResMed as of Q3 2016.

Based on Piermont Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.